Study of Pirtobrutinib for immune thrombocytopenia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new drug called pirtobrutinib for people with immune thrombocytopenia (ITP) who have not responded well to other treatments. The goal is to see if it can help raise your platelet count and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have primary ITP that is not caused by another condition
- You must have tried at least one prior treatment that worked for a while but stopped working or you stopped responding
- Your platelet count must be below 30,000 on two separate tests within 2 weeks before joining
- You cannot have had a blood transfusion or plasmapheresis in the last 2 to 4 weeks
- You cannot have a history of blood clots, heart disease, or certain cancers in the past year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called budoprutug for people with immune thrombocytopenia (ITP), a condition where your immune system attacks your own platelets, causing low counts. The study aims to see if the drug can safely raise platelet levels and reduce bleeding risk.
This study tests whether adding a second medication (Iguratimod) to a lower dose of rituximab helps people with a blood condition called ITP who have not responded well to steroids. The goal is to see if the combination is more effective than rituximab alone at raising and keeping platelet counts stable.
This trial tests an oral medicine called rilzabrutinib for adults with immune thrombocytopenia (ITP) whose first treatment stopped working or who need steroids long-term. The goal is to see if it helps raise platelet counts and reduce bleeding risk.
This study tests a new combination of two medicines—one that calms the immune system and one that helps your body make more platelets. It is for people with long-term ITP who have already tried other treatments and still have low platelet counts.
This Phase 2 study looks at zanubrutinib, a new medication, in people with immune thrombocytopenia (ITP) whose low platelet count has lasted more than 3 months and has not responded to prior steroid and other treatments. It may help raise platelets and reduce bleeding risk when other therapies have not worked.
This study tests a new drug, pirtobrutinib, for people with certain types of B-cell lymphoma who have already tried a similar drug (called a BTK inhibitor) and it stopped working or caused side effects. The goal is to see how well it works in real life.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.